These molecular features are strikingly different from those seen in NSCLC, in which various oncogenic driver mutations/fusions prevail (e.g., EGFR, KRAS, ALK, BRAF, RET, ROS1, MET, NTRK1-3, HER2/ERBB2) [22,23]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.